Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder

The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients

Shilpa Medicare has received DCG(i) approval for 2-Deoxy2-Glucose (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare Limited, API facility in Raichur,' Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana.

 2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with the brand name '2-DGSHIL'.